Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134974 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
A Phase 3 study of Mydriasis and Dilation, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 368
- Enrollment target
- 15
- Study locations
NCT05134974 is a Phase 3 study of Mydriasis and Dilation that has completed, run by Ocuphire Pharma. The registered enrollment target is 368 participants. The trial reports 15 study locations across 12 states.
The verdict
NCT05134974, a Phase 3 study of Mydriasis and Dilation, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 368 participants
- Enrollment target
- 15
- Study locations
Study Summary
The objectives of this study are: * To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine * To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) * To evaluate the safety of Nyxol * To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis * To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling
Interventions
- DRUG Phentolamine Ophthalmic Solution 0.75%
- DRUG Phentolamine Ophthalmic Solution Vehicle
Study Locations (15)
California
- Clinical Site 10 - Newport Beach
- Clinical Site 12 - Westminster
Florida
- Clinical Site 9 - Delray Beach
- Clinical Site 8 - Longwood
Georgia
- Clinical Site 6 - Morrow
- Clinical Site 1 - Roswell
Illinois
- Clinical Site 13 - Lake Villa
Kansas
- Clinical Site 5 - Pittsburg
Minnesota
- Clinical Site 2 - Bloomington
North Carolina
- Clinical Site 15 - Garner
Ohio
- Clinical Site 4 - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05134974
The ClinicalTrials.gov registry entry for NCT05134974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mydriasis appearing as the primary indexed condition, and to 2 interventions - of which Phentolamine Ophthalmic Solution 0.75% is the first listed.
NCT05134974 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05134974 about?
NCT05134974 is a clinical study titled "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)". The objectives of this study are: * To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine * To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (...
What is the current status of trial NCT05134974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 368 participants. The study started on 2021-11-18. Estimated completion is 2022-03-29.
What conditions does trial NCT05134974 study?
This clinical trial studies the following conditions: Mydriasis, Dilation.
What interventions are being tested in trial NCT05134974?
The interventions under investigation include: Phentolamine Ophthalmic Solution 0.75% (DRUG), Phentolamine Ophthalmic Solution Vehicle (DRUG).
Who is sponsoring clinical trial NCT05134974?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05134974 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mydriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.